期刊文献+

二肽基肽酶-4抑制药研究进展 被引量:3

Research Progress in Dipeptidyl Peptidase-4 Inhibitors
下载PDF
导出
摘要 二肽基肽酶-4(DPP-4)抑制药是一类新型口服降糖药,可改善血糖控制,并且不会增加体质量和诱发低血糖,在2型糖尿病的治疗中发挥着越来越重要的作用。本文对DPP-4抑制药作用机制、药动学及临床应用等方面的研究进展进行综述,以期为临床应用提供一定参考。 Dipeptidyl peptidase-4 (DPP-4) inhibitors, a new kind of oral hypoglycemic drugs, can significantly lower blood glu-cose levels in the patients with type 2 diabetes without common side effects such as body weight gain, hypoglycemia and gastrointestinal disturbances. Therefore, DPP-4 inhibitors play an increasingly important role in the treatment of type 2 diabetes. In this review, the re-search progress in the action mechanism, pharmacokinetics and clinical applications of DPP-4 inhibitors was summarized in order to provide reference for the clinical application.
作者 曹凤 吴方建
出处 《中国药师》 CAS 2014年第4期667-670,共4页 China Pharmacist
关键词 二肽基肽酶-4抑制药 2型糖尿病 研究进展 DPP-4 inhibitors Type 2 diabetes mellitus Research progress
  • 相关文献

参考文献24

  • 1Duez H,Cariou B,Staels B.DPP4 inhibitors in the treatment of type 2 diabetes[J].Biochem Pharmacol,2012,83(7):823-832. 被引量:1
  • 2Scheen AJ.Phannacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes[J].Expert Opin Drug Metab Toxicol,2012,8(6):745. 被引量:1
  • 3Barnett A.DPP4 inhibitors and their potential role in the management of type 2 diabetes [J].Int J Clin Pract,2006,60(11):1454-1470. 被引量:1
  • 4Mentlein R.Dipeptidyl-peptidase IV(CD26)role in the inactivation of regulatory peptides [J].Regul Pept,2009,85(1):9-24. 被引量:1
  • 5He YL,Sabo R,Campestrini J,et al.The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV(DPP4)inhibitor vildagliptin[J].Eur J Clin Pharmacol,2007,63(7):677-686. 被引量:1
  • 6张儒雅,陆菊明.DPP-4抑制剂在2型糖尿病治疗中的应用[J].中华内分泌代谢杂志,2011,27(1):101-104. 被引量:75
  • 7Takeda Y,Fujita Y,Honjo J,et al.Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase4 inhibition in a streptozotocin-induced model of diabetes in mice[J].Diabetologia,2012,55(2):404412. 被引量:1
  • 8Monami M,Lamanna C,Desideri CM,et al.DPP4 inhibitors and I ipids,systematic review and meta-analysis [J].Ad:Ther,2012,29(1):14-25. 被引量:1
  • 9朱翊,傅得兴.二肽基肽酶Ⅳ抑制剂的研究进展[J].中国药学杂志,2007,42(17):1284-1286. 被引量:7
  • 10Defronzo RA,Fleck PR,Wilson CA,et al.Efficacy and safety of the dipeptidyl peptidase4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control[J].Diabetes Care,2008.31(12):2315-2317. 被引量:1

二级参考文献70

  • 1Goke B.Islet cell function:alpha and beta cells-partners towards normoglycaemia.Int J Clin Pract Suppl,2008,(159):2-7. 被引量:1
  • 2Kim MH,Lee MK.The incretins and pancreatic beta-cells:use of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide to cure type 2 diabetes Mellitus.Korean Diabetes J,2010,34:2-9. 被引量:1
  • 3Kim W,Egan JM.The role of incretins in glucose homeostasis and diabetes treatment.Pharmacol Rev,2008,60:470-512. 被引量:1
  • 4Neumiller JJ,Wood L,Campbell RK.Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.Pharmacotherapy,2010,30:463-484. 被引量:1
  • 5Deacon CF.Circulation and degradation of GIP and GLP-1.Horm Metab Res,2004,36:761-765. 被引量:1
  • 6Deacon CF,Carr RD,Holst JJ.DPP-4 inhibitor therapy:new directions in the treatment of type 2 diabetes.Front Biosci,2008,13:1780-1794. 被引量:1
  • 7Lankas GR,Leiting B,Roy RS,et al.Dipeptidyl peptidase Ⅳ inhibition for the treatment of type 2 diabetes:potential importance of selectivity over dipeptidyl peptidases 8 and 9.Diabetes,2005,54:2988 -2994. 被引量:1
  • 8Holst JJ,Deacon CF.Inhibition of the activity of dipeptidyl-peptidase Ⅳ as a treatment for type 2 diabetes.Diabetes,1998,47:1663-1670. 被引量:1
  • 9Ahren B,Holst JJ,Martensson H,et al.Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase Ⅳ in mice.Eur J Pharmacol,2000,404:239-245. 被引量:1
  • 10Mari A,Sallas WM,He YL,et al.Vildagliptin,a dipeptidyl peptidase-Ⅳ inhibitor,improves model-assessed beta-cell function in patients with type 2 diabetes.J Clin Endocrinol Metab,2005,90:4888-4894. 被引量:1

共引文献94

同被引文献57

  • 1Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China[ J ]. N Engl J Med, 2010, 362 (12) : 1090-1101. 被引量:1
  • 2汤森路透公司.Thomaon reuters cortellis数据库[EB/OL].https://cortellis.thomsortr euterslif esciences.com,2014-06-16 /2014-06-17. 被引量:1
  • 3Merck & CO Inc. Beta-amino tetrahydroimidazo (1, 2-A) pyraz/nes and tetrahydrotrioazolo (4,3-A) pyrazines as dipeptidyl peptidase inhibi- tors for the treatment or prevention of diabetes[ P]. 世界知识产权组织:W003004498A1,2002-07-05. 被引量:1
  • 4Merck & CO Inc. Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor[ P]. 世界知识产权组织: WO2005003135A1,2004-06-18. 被引量:1
  • 5Merck & CO Inc. Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-lV inhibitor [ P ]. 世界知识产权组织: WO2005020920A2, 2004-08-27. 被引量:1
  • 6Merck & CO Inc. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin [ P].世界知识产权组织 : WO2007078726A2, 2006-12-12. 被引量:1
  • 7Merck & CO Inc. Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-lV inhibitor[ P].世界知识产权组织: W02009111200A1, 2009-02-23. 被引量:1
  • 8Novartis AG. N-substituted 2-cyanopyrrolidines [ P ] .世界知识产权组织: W00034241 A1, 1999-12-09. 被引量:1
  • 9Novartis AG. Process for the preparation of N-substituted 2-cyanotryrro- lidines [ P]. 世界知识产权组织: WO2004092127AI, 2004-04-15. 被引量:1
  • 10Novartis AG. Direct compression formulation and process [ P]. 世界知识产权组织:WO2005067976A2, 2005-01-17. 被引量:1

二级引证文献65

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部